Independent · Educational
2026 is the year US peptide rules are being rewritten — and GLP-1 weight-loss access is moving the opposite way. We explain what's legal, what it costs and how to choose a provider, in plain language. We don't sell or supply anything.
The 2026 story at a glance
Peptides · opening up
In April 2026 the FDA removed 12 research peptides — including BPC-157 and TB-500 — from its Category 2 "do not compound" list. That is not approval: each must still clear an FDA advisory-committee review on July 23–24, 2026 before legal compounding can resume. For now they sit in limbo.
Read the full breakdown →GLP-1s · tightening
With the shortages over, the FDA proposed in April 2026 to bar large-scale (503B) compounding of semaglutide and tirzepatide. Patient-specific (503A) compounding and brand-name access — NovoCare, LillyDirect — remain, but the cheap mass-compounded era is ending.
Where GLP-1 access stands →Explore the site
What's legal, what's compoundable, and how the 2026 rules actually work — peptides and GLP-1s.
GLP-1 medications — Ozempic, Wegovy, Zepbound, Mounjaro — costs, insurance coverage and comparisons.
Plain-English explainers for each peptide: what it is, what the research shows, timelines and cost.
How to choose a provider, what to expect from therapy, and balanced side-effect overviews.
Peptide and GLP-1 clinic guides for major US cities, from New York to Los Angeles.
Who we are, how we research these pages, and why we never sell or supply products.
Start here
Basics
A plain-English guide to what peptides are and how they're used — before the marketing spin.
Access
What actually changed in April 2026, what didn't, and what the July advisory review decides.
Weight loss
How semaglutide and tirzepatide drugs work, what they cost, and how access works now.
Compare
The two leading GLP-1 drugs side by side on results, cost and tolerability.
Guide
The questions to ask, the red flags to avoid, and how to verify licensing yourself.
Access
The honest 2026 answer — by compound, by route, and by what each status really means.
Compound explainers
Each explainer covers what the compound is, what the evidence actually shows, and its current US legal standing — with no dosing instructions and no sourcing advice.
By location
City guides covering how peptide and GLP-1 access works locally — telehealth, in-person clinics and what to verify before you book.
We're an independent resource, not a clinic and not a pharmacy. Our job is to explain the landscape clearly so you can make your own decisions.
We don't sell or supply products. No pharmacy, no inventory, no kickback on what you buy.
Regulatory facts are dated and sourced. The 2026 rules are moving fast; every status note reflects the current FDA position.
Education, not prescriptions. Nothing here is medical advice or a substitute for a licensed clinician.
Ask a question
Tell us what you're trying to understand — access, costs, a specific compound or a provider — and we'll point you to the right pages. General information only, never sales pressure.